Gaucher Disease Type 1 Epidemiology Forecast 2025-2034

Gaucher disease type 1 epidemiology forecast suggests that Gaucher disease type 1 affects more than 90% of Gaucher disease patients across North America and Europe, with splenomegaly, hepatomegaly, and blood and bone abnormalities as the primary clinical presentations. As per the Orphanet, the prevalence of Gaucher disease type 1 is estimated to be 1 to 9 per 100,000.

Gaucher Disease Type 1 Epidemiology Forecast Report Coverage

The “Gaucher Disease Type 1 Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of Gaucher disease type 1. It projects the future incidence and prevalence rates of Gaucher disease type 1 cases across various populations. The study covers age and type as major determinants of the Gaucher disease type 1 population. The report highlights patterns in the prevalence of Gaucher disease type 1 over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on Gaucher disease type 1 epidemiology in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Gaucher Disease Type 1 Understanding: Disease Overview

Gaucher disease type 1 refers to a rare inherited disorder caused by a deficiency of the enzyme glucocerebrosidase. In this genetic disease, accumulation of glucocerebroside occurs in organs such as the liver, spleen, and bone marrow. This buildup results in symptoms like bone pain, fractures, enlarged liver and spleen (hepatosplenomegaly), fatigue, easy bruising, and anemia, among others. Some patients may also experience serious complications, including bone damage and organ dysfunction.

Gaucher disease Type 1 is not associated with neurological symptoms, unlike other types of Gaucher disease. It is inherited in an autosomal recessive manner, with both parents carrying the defective gene for the child to be affected.

Gaucher Disease Type 1 Epidemiology Perspective

The Gaucher disease type 1 epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The publisher provides both current and predicted trends for Gaucher disease type 1 epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for the disease and their trends. The Gaucher disease type 1 detailed epidemiology segmentation is broken down into specific categories, such as the total diagnosed cases across different age groups and patient pools.

• According to a 2022 targeted literature review, the incidence of Gaucher disease across all types ranged from 0.45 to 25.0 per 100,000 live births, with the lowest rates observed in the Asia-Pacific region. The incidence of Gaucher disease type 1 ranged from 0.45 to 22.9 per 100,000 live births in Europe and North America. Further, type-specific prevalence estimates per 100,000 population for Gaucher disease type 1 were reported to range from 0.26 to 0.63.
• The prevalence of Gaucher disease type 1 is estimated to be 1 to 9 per 100,000 worldwide, as per Orphanet.
• The incidence of Gaucher disease is influenced by ethnicity, with higher rates observed in specific populations, particularly among those of Ashkenazi Jewish descent, where the estimated frequency for Gaucher disease type 1 is about 1 in 450 births.
• Clinical or radiographic evidence of bone disease is present in 70% to 100% of people with type 1 Gaucher disease, as per Hughes et al., 2019.

Country-wise Gaucher Disease Type 1 Epidemiology Segment

The Gaucher disease type 1 epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of Gaucher disease type 1 varies significantly between countries due to differences in factors such as genetic predisposition, healthcare access, and diagnostic practices, among others. Type 1 Gaucher disease is the most common form of the disease in Western countries, including the United States. As of 2018, it is estimated that about 6,000 Americans have been diagnosed with Gaucher disease.

Gaucher Disease Type 1: Treatment Overview

Gaucher disease type 1 therapeutics are used for managing symptoms, reducing complications, and improving the quality of life of the affected individual. Enzyme replacement therapy (ERT) and substrate reduction therapy (SRT) are the primary Gaucher disease type 1 treatment options. ERT involves regular intravenous infusions of synthetic glucocerebrosidase, which helps reduce the buildup of glucocerebroside in organs.

Common ERT medications include imiglucerase, velaglucerase alfa, and taliglucerase alfa. On the other hand, substrate reduction therapy helps reduce the production of glucocerebroside in Gaucher disease type 1 patients. Medications such as eliglustat and miglustat are used in SRT and may be combined with enzyme replacement therapy in certain Gaucher disease type 1 cases.

Key Questions Answered

• What are the key findings of Gaucher disease type 1 epidemiology in the 8 major markets?
• What will be the total number of patients with Gaucher disease type 1 across the 8 major markets during the forecast period?
• What was the country-wise Gaucher disease type 1 epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of Gaucher disease type 1 patients during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of Gaucher disease type 1 during the forecast period of 2025-2034?
• What are the currently available treatments in the Gaucher disease type 1 market?
• What are the disease risks, signs, symptoms, and unmet needs of Gaucher disease type 1?

Scope of the Gaucher Disease Type 1 Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of Gaucher disease type 1 based on several factors.
• The Gaucher Disease Type 1 Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The Gaucher disease type 1 report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

This product will be delivered within 3-5 business days.